25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

CU6 (Clarity Pharmaceuticals Ltd) Stock Analysis
Buy, Hold or Sell?

Let's analyze Clarity Pharmaceuticals Ltd together

I guess you are interested in Clarity Pharmaceuticals Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Clarity Pharmaceuticals Ltd’s Financial Insights
  • 📈 Technical Analysis (TA) – Clarity Pharmaceuticals Ltd’s Price Targets

I'm going to help you getting a better view of Clarity Pharmaceuticals Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Clarity Pharmaceuticals Ltd

I send you an email if I find something interesting about Clarity Pharmaceuticals Ltd.

1. Quick Overview

1.1. Quick analysis of Clarity Pharmaceuticals Ltd (30 sec.)










1.2. What can you expect buying and holding a share of Clarity Pharmaceuticals Ltd? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
A$0.46
Expected worth in 1 year
A$1.42
How sure are you?
71.4%

+ What do you gain per year?

Total Gains per Share
A$0.96
Return On Investment
41.9%

For what price can you sell your share?

Current Price per Share
A$2.29
Expected price per share
A$1.19 - A$2.5
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Clarity Pharmaceuticals Ltd (5 min.)




Live pricePrice per Share (EOD)
A$2.29
Intrinsic Value Per Share
A$-2.03 - A$-1.64
Total Value Per Share
A$-1.57 - A$-1.19

2.2. Growth of Clarity Pharmaceuticals Ltd (5 min.)




Is Clarity Pharmaceuticals Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$94m$44.4m$49.5m52.7%

How much money is Clarity Pharmaceuticals Ltd making?

Current yearPrevious yearGrowGrow %
Making money-$27.1m-$15.8m-$11.3m-41.9%
Net Profit Margin-367.8%-251.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Clarity Pharmaceuticals Ltd (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#346 / 889

Most Revenue
#312 / 889

Most Profit
#694 / 889

Most Efficient
#617 / 889
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Clarity Pharmaceuticals Ltd?

Welcome investor! Clarity Pharmaceuticals Ltd's management wants to use your money to grow the business. In return you get a share of Clarity Pharmaceuticals Ltd.

First you should know what it really means to hold a share of Clarity Pharmaceuticals Ltd. And how you can make/lose money.

Speculation

The Price per Share of Clarity Pharmaceuticals Ltd is A$2.29. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Clarity Pharmaceuticals Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Clarity Pharmaceuticals Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.46. Based on the TTM, the Book Value Change Per Share is A$0.24 per quarter. Based on the YOY, the Book Value Change Per Share is A$-0.07 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Clarity Pharmaceuticals Ltd.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.08-3.7%-0.08-3.7%-0.05-2.1%-0.06-2.6%-0.04-1.9%-0.03-1.4%
Usd Book Value Change Per Share0.156.7%0.156.7%-0.05-2.0%0.083.7%0.052.4%0.041.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.156.7%0.156.7%-0.05-2.0%0.083.7%0.052.4%0.041.8%
Usd Price Per Share3.48-3.48-0.45-1.42-0.85-0.61-
Price to Earnings Ratio-41.15--41.15--9.14--19.06--11.44--8.17-
Price-to-Total Gains Ratio22.58-22.58--9.75-5.04-5.04-5.04-
Price to Book Ratio11.91-11.91-3.25-5.64-3.39-2.42-
Price-to-Total Gains Ratio22.58-22.58--9.75-5.04-5.04-5.04-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.471554
Number of shares679
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.150.05
Usd Total Gains Per Share0.150.05
Gains per Quarter (679 shares)104.7137.22
Gains per Year (679 shares)418.86148.89
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
104194090149139
208388280298288
30125712470447437
40167516660596586
50209420850744735
60251325040893884
7029322923010421033
8033513342011911182
9037703761013401331
10041894180014891480

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.07.00.00.0%0.07.00.00.0%
Book Value Change Per Share1.00.00.0100.0%2.01.00.066.7%3.02.00.060.0%5.02.00.071.4%5.02.00.071.4%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.07.00.0%0.00.07.00.0%
Total Gains per Share1.00.00.0100.0%2.01.00.066.7%3.02.00.060.0%5.02.00.071.4%5.02.00.071.4%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Clarity Pharmaceuticals Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.2400.2400%-0.072+130%0.131+84%0.085+181%0.065+269%
Book Value Per Share--0.4550.4550%0.215+111%0.319+43%0.209+118%0.154+195%
Current Ratio--19.04619.0460%10.167+87%14.158+35%12.408+54%10.617+79%
Debt To Asset Ratio--0.0540.0540%0.100-46%0.077-30%0.088-39%0.122-56%
Debt To Equity Ratio--0.0570.0570%0.112-49%0.084-32%0.097-41%0.150-62%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--1869901745.0001869901745.0000%282240582.000+563%800260922.000+134%800260922.000+134%800260922.000+134%
Eps---0.132-0.1320%-0.077-42%-0.094-29%-0.067-49%-0.050-62%
Ev To Ebitda Ratio---41.881-41.8810%-10.747-74%-22.418-46%-22.418-46%-22.418-46%
Ev To Sales Ratio--162.506162.5060%28.798+464%76.600+112%76.600+112%76.600+112%
Free Cash Flow Per Share---0.136-0.1360%-0.086-37%-0.088-35%-0.062-55%-0.047-66%
Free Cash Flow To Equity Per Share--0.2220.2220%-0.085+138%0.122+82%0.076+193%0.055+307%
Gross Profit Margin--1.0041.0040%1.105-9%1.036-3%1.108-9%1.426-30%
Intrinsic Value_10Y_max---1.644----------
Intrinsic Value_10Y_min---2.028----------
Intrinsic Value_1Y_max---0.084----------
Intrinsic Value_1Y_min---0.118----------
Intrinsic Value_3Y_max---0.314----------
Intrinsic Value_3Y_min---0.431----------
Intrinsic Value_5Y_max---0.619----------
Intrinsic Value_5Y_min---0.824----------
Market Cap735896080.000-137%1741727840.0001741727840.0000%224946400.000+674%710187920.000+145%426112752.000+309%304366251.429+472%
Net Profit Margin---3.678-3.6780%-2.510-32%-3.289-11%-3.112-15%-2.521-31%
Operating Margin---3.893-3.8930%-2.690-31%-3.074-21%-2.996-23%-2.444-37%
Operating Ratio--4.9074.9070%3.690+33%4.431+11%4.210+17%3.597+36%
Pb Ratio5.030-137%11.90511.9050%3.252+266%5.645+111%3.387+252%2.419+392%
Pe Ratio-17.387+58%-41.152-41.1520%-9.143-78%-19.065-54%-11.439-72%-8.171-80%
Price Per Share2.290-137%5.4205.4200%0.700+674%2.210+145%1.326+309%0.947+472%
Price To Free Cash Flow Ratio-16.824+58%-39.819-39.8190%-8.166-79%-20.034-50%-12.020-70%-8.586-78%
Price To Total Gains Ratio9.542-137%22.58422.5840%-9.754+143%5.036+348%5.036+348%5.036+348%
Quick Ratio--29.39229.3920%14.428+104%20.646+42%17.399+69%14.733+99%
Return On Assets---0.274-0.2740%-0.320+17%-0.277+1%-0.409+50%-0.431+58%
Return On Equity---0.289-0.2890%-0.356+23%-0.301+4%-0.452+56%-0.507+75%
Total Gains Per Share--0.2400.2400%-0.072+130%0.131+84%0.085+181%0.065+269%
Usd Book Value--94010741.37094010741.3700%44452284.257+111%65911407.458+43%43201500.242+118%31882273.753+195%
Usd Book Value Change Per Share--0.1540.1540%-0.046+130%0.084+84%0.055+181%0.042+269%
Usd Book Value Per Share--0.2930.2930%0.138+111%0.205+43%0.134+118%0.099+195%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--1201598861.3371201598861.3370%181367797.993+563%514247668.477+134%514247668.477+134%514247668.477+134%
Usd Eps---0.085-0.0850%-0.049-42%-0.060-29%-0.043-49%-0.032-62%
Usd Free Cash Flow---28108036.001-28108036.0010%-17701393.109-37%-18167307.241-35%-12774485.989-55%-9604502.386-66%
Usd Free Cash Flow Per Share---0.087-0.0870%-0.055-37%-0.057-35%-0.040-55%-0.030-66%
Usd Free Cash Flow To Equity Per Share--0.1430.1430%-0.055+138%0.078+82%0.049+193%0.035+307%
Usd Market Cap472886821.008-137%1119234309.9841119234309.9840%144550556.640+674%456366757.392+145%273820054.435+309%195585753.168+472%
Usd Price Per Share1.472-137%3.4833.4830%0.450+674%1.420+145%0.852+309%0.609+472%
Usd Profit---27197677.433-27197677.4330%-15809531.800-42%-19423968.089-29%-13861741.542-49%-10397280.118-62%
Usd Revenue--7394182.9297394182.9290%6297837.286+17%5947508.473+24%4337732.627+70%3566943.988+107%
Usd Total Gains Per Share--0.1540.1540%-0.046+130%0.084+84%0.055+181%0.042+269%
 EOD+2 -6MRQTTM+0 -0YOY+25 -133Y+25 -135Y+25 -1310Y+25 -13

3.3 Fundamental Score

Let's check the fundamental score of Clarity Pharmaceuticals Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-17.387
Price to Book Ratio (EOD)Between0-15.030
Net Profit Margin (MRQ)Greater than0-3.678
Operating Margin (MRQ)Greater than0-3.893
Quick Ratio (MRQ)Greater than129.392
Current Ratio (MRQ)Greater than119.046
Debt to Asset Ratio (MRQ)Less than10.054
Debt to Equity Ratio (MRQ)Less than10.057
Return on Equity (MRQ)Greater than0.15-0.289
Return on Assets (MRQ)Greater than0.05-0.274
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Clarity Pharmaceuticals Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.512
Ma 20Greater thanMa 502.355
Ma 50Greater thanMa 1002.234
Ma 100Greater thanMa 2002.952
OpenGreater thanClose2.270
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Clarity Pharmaceuticals Ltd

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development and clinical stage radiopharmaceuticals products in Australia and the United States. The company's products include SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2; developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. It develops theranostic therapy and imaging products for the treatment of cancer in children and adults. The company was incorporated in 2010 and is based in Sydney, Australia.

Fundamental data was last updated by Penke on 2025-05-15 18:19:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Clarity Pharmaceuticals Ltd earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Clarity Pharmaceuticals Ltd to the Biotechnology industry mean.
  • A Net Profit Margin of -367.8% means that $-3.68 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Clarity Pharmaceuticals Ltd:

  • The MRQ is -367.8%. The company is making a huge loss. -2
  • The TTM is -367.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-367.8%TTM-367.8%0.0%
TTM-367.8%YOY-251.0%-116.8%
TTM-367.8%5Y-311.2%-56.7%
5Y-311.2%10Y-252.1%-59.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-367.8%-84.4%-283.4%
TTM-367.8%-169.6%-198.2%
YOY-251.0%-193.2%-57.8%
3Y-328.9%-253.9%-75.0%
5Y-311.2%-345.1%+33.9%
10Y-252.1%-474.1%+222.0%
4.3.1.2. Return on Assets

Shows how efficient Clarity Pharmaceuticals Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Clarity Pharmaceuticals Ltd to the Biotechnology industry mean.
  • -27.4% Return on Assets means that Clarity Pharmaceuticals Ltd generated $-0.27 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Clarity Pharmaceuticals Ltd:

  • The MRQ is -27.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -27.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-27.4%TTM-27.4%0.0%
TTM-27.4%YOY-32.0%+4.6%
TTM-27.4%5Y-40.9%+13.6%
5Y-40.9%10Y-43.1%+2.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-27.4%-11.2%-16.2%
TTM-27.4%-11.4%-16.0%
YOY-32.0%-11.1%-20.9%
3Y-27.7%-11.6%-16.1%
5Y-40.9%-12.2%-28.7%
10Y-43.1%-14.0%-29.1%
4.3.1.3. Return on Equity

Shows how efficient Clarity Pharmaceuticals Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Clarity Pharmaceuticals Ltd to the Biotechnology industry mean.
  • -28.9% Return on Equity means Clarity Pharmaceuticals Ltd generated $-0.29 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Clarity Pharmaceuticals Ltd:

  • The MRQ is -28.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -28.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-28.9%TTM-28.9%0.0%
TTM-28.9%YOY-35.6%+6.6%
TTM-28.9%5Y-45.2%+16.2%
5Y-45.2%10Y-50.7%+5.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-28.9%-14.0%-14.9%
TTM-28.9%-14.5%-14.4%
YOY-35.6%-14.7%-20.9%
3Y-30.1%-17.1%-13.0%
5Y-45.2%-17.5%-27.7%
10Y-50.7%-19.7%-31.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Clarity Pharmaceuticals Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Clarity Pharmaceuticals Ltd is operating .

  • Measures how much profit Clarity Pharmaceuticals Ltd makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Clarity Pharmaceuticals Ltd to the Biotechnology industry mean.
  • An Operating Margin of -389.3% means the company generated $-3.89  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Clarity Pharmaceuticals Ltd:

  • The MRQ is -389.3%. The company is operating very inefficient. -2
  • The TTM is -389.3%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-389.3%TTM-389.3%0.0%
TTM-389.3%YOY-269.0%-120.3%
TTM-389.3%5Y-299.6%-89.7%
5Y-299.6%10Y-244.4%-55.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-389.3%-189.1%-200.2%
TTM-389.3%-300.6%-88.7%
YOY-269.0%-208.4%-60.6%
3Y-307.4%-235.8%-71.6%
5Y-299.6%-350.5%+50.9%
10Y-244.4%-449.7%+205.3%
4.3.2.2. Operating Ratio

Measures how efficient Clarity Pharmaceuticals Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 4.91 means that the operating costs are $4.91 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Clarity Pharmaceuticals Ltd:

  • The MRQ is 4.907. The company is inefficient in keeping operating costs low. -1
  • The TTM is 4.907. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ4.907TTM4.9070.000
TTM4.907YOY3.690+1.217
TTM4.9075Y4.210+0.697
5Y4.21010Y3.597+0.613
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.9072.060+2.847
TTM4.9072.936+1.971
YOY3.6903.030+0.660
3Y4.4313.729+0.702
5Y4.2104.834-0.624
10Y3.5976.406-2.809
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Clarity Pharmaceuticals Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Clarity Pharmaceuticals Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 19.05 means the company has $19.05 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Clarity Pharmaceuticals Ltd:

  • The MRQ is 19.046. The company is very able to pay all its short-term debts. +2
  • The TTM is 19.046. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ19.046TTM19.0460.000
TTM19.046YOY10.167+8.879
TTM19.0465Y12.408+6.639
5Y12.40810Y10.617+1.791
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ19.0463.602+15.444
TTM19.0463.930+15.116
YOY10.1674.255+5.912
3Y14.1584.778+9.380
5Y12.4085.833+6.575
10Y10.6176.209+4.408
4.4.3.2. Quick Ratio

Measures if Clarity Pharmaceuticals Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Clarity Pharmaceuticals Ltd to the Biotechnology industry mean.
  • A Quick Ratio of 29.39 means the company can pay off $29.39 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Clarity Pharmaceuticals Ltd:

  • The MRQ is 29.392. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 29.392. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ29.392TTM29.3920.000
TTM29.392YOY14.428+14.963
TTM29.3925Y17.399+11.992
5Y17.39910Y14.733+2.666
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ29.3922.872+26.520
TTM29.3923.417+25.975
YOY14.4284.024+10.404
3Y20.6464.605+16.041
5Y17.3995.882+11.517
10Y14.7336.528+8.205
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Clarity Pharmaceuticals Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Clarity Pharmaceuticals Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Clarity Pharmaceuticals Ltd to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.05 means that Clarity Pharmaceuticals Ltd assets are financed with 5.4% credit (debt) and the remaining percentage (100% - 5.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Clarity Pharmaceuticals Ltd:

  • The MRQ is 0.054. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.054. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.054TTM0.0540.000
TTM0.054YOY0.100-0.047
TTM0.0545Y0.088-0.034
5Y0.08810Y0.122-0.035
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0540.342-0.288
TTM0.0540.346-0.292
YOY0.1000.335-0.235
3Y0.0770.331-0.254
5Y0.0880.353-0.265
10Y0.1220.379-0.257
4.5.4.2. Debt to Equity Ratio

Measures if Clarity Pharmaceuticals Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Clarity Pharmaceuticals Ltd to the Biotechnology industry mean.
  • A Debt to Equity ratio of 5.7% means that company has $0.06 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Clarity Pharmaceuticals Ltd:

  • The MRQ is 0.057. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.057. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.057TTM0.0570.000
TTM0.057YOY0.112-0.055
TTM0.0575Y0.097-0.040
5Y0.09710Y0.150-0.053
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0570.410-0.353
TTM0.0570.428-0.371
YOY0.1120.415-0.303
3Y0.0840.434-0.350
5Y0.0970.459-0.362
10Y0.1500.498-0.348
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Clarity Pharmaceuticals Ltd generates.

  • Above 15 is considered overpriced but always compare Clarity Pharmaceuticals Ltd to the Biotechnology industry mean.
  • A PE ratio of -41.15 means the investor is paying $-41.15 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Clarity Pharmaceuticals Ltd:

  • The EOD is -17.387. Based on the earnings, the company is expensive. -2
  • The MRQ is -41.152. Based on the earnings, the company is expensive. -2
  • The TTM is -41.152. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-17.387MRQ-41.152+23.765
MRQ-41.152TTM-41.1520.000
TTM-41.152YOY-9.143-32.009
TTM-41.1525Y-11.439-29.713
5Y-11.43910Y-8.171-3.268
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-17.387-1.792-15.595
MRQ-41.152-2.336-38.816
TTM-41.152-2.883-38.269
YOY-9.143-3.425-5.718
3Y-19.065-4.006-15.059
5Y-11.439-6.234-5.205
10Y-8.171-6.709-1.462
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Clarity Pharmaceuticals Ltd:

  • The EOD is -16.824. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -39.819. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -39.819. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-16.824MRQ-39.819+22.995
MRQ-39.819TTM-39.8190.000
TTM-39.819YOY-8.166-31.653
TTM-39.8195Y-12.020-27.799
5Y-12.02010Y-8.586-3.434
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-16.824-2.621-14.203
MRQ-39.819-3.120-36.699
TTM-39.819-3.779-36.040
YOY-8.166-4.126-4.040
3Y-20.034-5.271-14.763
5Y-12.020-8.214-3.806
10Y-8.586-9.113+0.527
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Clarity Pharmaceuticals Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 11.91 means the investor is paying $11.91 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Clarity Pharmaceuticals Ltd:

  • The EOD is 5.030. Based on the equity, the company is overpriced. -1
  • The MRQ is 11.905. Based on the equity, the company is expensive. -2
  • The TTM is 11.905. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD5.030MRQ11.905-6.875
MRQ11.905TTM11.9050.000
TTM11.905YOY3.252+8.654
TTM11.9055Y3.387+8.519
5Y3.38710Y2.419+0.968
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.0301.819+3.211
MRQ11.9052.078+9.827
TTM11.9052.357+9.548
YOY3.2522.417+0.835
3Y5.6452.716+2.929
5Y3.3873.661-0.274
10Y2.4194.303-1.884
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets154,629
Total Liabilities8,332
Total Stockholder Equity146,297
 As reported
Total Liabilities 8,332
Total Stockholder Equity+ 146,297
Total Assets = 154,629

Assets

Total Assets154,629
Total Current Assets154,061
Long-term Assets568
Total Current Assets
Cash And Cash Equivalents 47,901
Short-term Investments 88,605
Net Receivables 12,635
Other Current Assets 4,921
Total Current Assets  (as reported)154,061
Total Current Assets  (calculated)154,061
+/-0
Long-term Assets
Property Plant Equipment 555
Long Term Investments 13
Long-term Assets  (as reported)568
Long-term Assets  (calculated)568
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities8,089
Long-term Liabilities243
Total Stockholder Equity146,297
Total Current Liabilities
Accounts payable 2,084
Other Current Liabilities 5,790
Total Current Liabilities  (as reported)8,089
Total Current Liabilities  (calculated)7,875
+/- 214
Long-term Liabilities
Long-term Liabilities  (as reported)243
Long-term Liabilities  (calculated)0
+/- 243
Total Stockholder Equity
Common Stock249,447
Retained Earnings -112,699
Accumulated Other Comprehensive Income 9,549
Total Stockholder Equity (as reported)146,297
Total Stockholder Equity (calculated)146,297
+/-0
Other
Capital Stock249,447
Cash and Short Term Investments 136,506
Common Stock Shares Outstanding 273,158
Liabilities and Stockholders Equity 154,629
Net Debt -47,901
Net Invested Capital 146,297
Net Working Capital 145,972
Property Plant and Equipment Gross 929



6.2. Balance Sheets Structured

Currency in AUD. All numbers in thousands.

 Trend2024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-30
> Total Assets 
2,786
10,362
9,115
22,613
99,822
76,896
154,629
154,62976,89699,82222,6139,11510,3622,786
   > Total Current Assets 
2,724
10,306
9,054
22,508
99,550
76,678
154,061
154,06176,67899,55022,5089,05410,3062,724
       Cash And Cash Equivalents 
1,677
3,891
5,265
8,439
55,336
65,015
47,901
47,90165,01555,3368,4395,2653,8911,677
       Short-term Investments 
0
4,523
1,000
10,500
37,000
33,802
88,605
88,60533,80237,00010,5001,0004,5230
       Net Receivables 
1,047
1,736
2,660
3,372
6,658
10,002
12,635
12,63510,0026,6583,3722,6601,7361,047
       Other Current Assets 
813
1,893
2,789
3,569
556
1,661
4,921
4,9211,6615563,5692,7891,893813
   > Long-term Assets 
63
56
61
105
272
218
568
568218272105615663
       Property Plant Equipment 
60
53
50
93
260
206
555
55520626093505360
       Long Term Investments 
0
0
0
0
12
12
13
1312120000
       Long-term Assets Other 
3
3
11
0
0
0
13
130001133
> Total Liabilities 
857
1,136
956
2,335
7,585
7,721
8,332
8,3327,7217,5852,3359561,136857
   > Total Current Liabilities 
857
1,132
947
2,251
7,506
7,542
8,089
8,0897,5427,5062,2519471,132857
       Accounts payable 
191
528
156
228
2,850
2,847
2,084
2,0842,8472,850228156528191
       Other Current Liabilities 
342
457
682
1,942
4,656
4,696
5,790
5,7904,6964,6561,942682457342
   > Long-term Liabilities 
0
4
9
85
79
179
243
2431797985940
       Other Liabilities 
0
4
9
85
79
179
0
01797985940
> Total Stockholder Equity
1,929
9,226
8,159
20,278
92,237
69,176
146,297
146,29769,17692,23720,2788,1599,2261,929
   Common Stock
8,217
18,963
23,933
44,904
132,115
132,820
249,447
249,447132,820132,11544,90423,93318,9638,217
   Retained Earnings -112,699-70,374-45,796-28,850-18,866-11,912-8,227
   Capital Surplus 0000000
   Treasury Stock0000000
   Other Stockholders Equity 
1,940
0
0
4,224
5,917
0
0
005,9174,224001,940



6.3. Balance Sheets

Currency in AUD. All numbers in thousands.




6.4. Cash Flows

Currency in AUD. All numbers in thousands.




6.5. Income Statements

Currency in AUD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-06-30. Currency in AUD. All numbers in thousands.

Gross Profit (+$)
totalRevenue11,507
Cost of Revenue-153
Gross Profit11,50711,354
 
Operating Income (+$)
Gross Profit11,507
Operating Expense-56,307
Operating Income-44,801-44,801
 
Operating Expense (+$)
Research Development45,783
Selling General Administrative10,354
Selling And Marketing Expenses171
Operating Expense56,30756,307
 
Net Interest Income (+$)
Interest Income2,771
Interest Expense-0
Other Finance Cost-0
Net Interest Income2,771
 
Pretax Income (+$)
Operating Income-44,801
Net Interest Income2,771
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-42,029-47,572
EBIT - interestExpense = -44,801
-42,029
-42,324
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-44,801-42,029
Earnings Before Interest and Taxes (EBITDA)-44,648
 
After tax Income (+$)
Income Before Tax-42,029
Tax Provision-295
Net Income From Continuing Ops-42,324-42,324
Net Income-42,324
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses56,307
Total Other Income/Expenses Net2,771-2,771
 

Technical Analysis of Clarity Pharmaceuticals Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Clarity Pharmaceuticals Ltd. The general trend of Clarity Pharmaceuticals Ltd is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Clarity Pharmaceuticals Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Clarity Pharmaceuticals Ltd Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Clarity Pharmaceuticals Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 2.5 < 2.5 < 2.5.

The bearish price targets are: 1.43 > 1.2 > 1.19.

Know someone who trades $CU6? Share this with them.👇

Clarity Pharmaceuticals Ltd Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Clarity Pharmaceuticals Ltd. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Clarity Pharmaceuticals Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Clarity Pharmaceuticals Ltd. The current macd is 0.03500258.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Clarity Pharmaceuticals Ltd price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Clarity Pharmaceuticals Ltd. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Clarity Pharmaceuticals Ltd price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Clarity Pharmaceuticals Ltd Daily Moving Average Convergence/Divergence (MACD) ChartClarity Pharmaceuticals Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Clarity Pharmaceuticals Ltd. The current adx is 20.99.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Clarity Pharmaceuticals Ltd shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Clarity Pharmaceuticals Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Clarity Pharmaceuticals Ltd. The current sar is 2.65000792.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Clarity Pharmaceuticals Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Clarity Pharmaceuticals Ltd. The current rsi is 49.51. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Clarity Pharmaceuticals Ltd Daily Relative Strength Index (RSI) ChartClarity Pharmaceuticals Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Clarity Pharmaceuticals Ltd. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Clarity Pharmaceuticals Ltd price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Clarity Pharmaceuticals Ltd Daily Stochastic Oscillator ChartClarity Pharmaceuticals Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Clarity Pharmaceuticals Ltd. The current cci is -51.75175175.

Clarity Pharmaceuticals Ltd Daily Commodity Channel Index (CCI) ChartClarity Pharmaceuticals Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Clarity Pharmaceuticals Ltd. The current cmo is -3.37966372.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Clarity Pharmaceuticals Ltd Daily Chande Momentum Oscillator (CMO) ChartClarity Pharmaceuticals Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Clarity Pharmaceuticals Ltd. The current willr is -76.47058824.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Clarity Pharmaceuticals Ltd is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Clarity Pharmaceuticals Ltd Daily Williams %R ChartClarity Pharmaceuticals Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Clarity Pharmaceuticals Ltd.

Clarity Pharmaceuticals Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Clarity Pharmaceuticals Ltd. The current atr is 0.2092648.

Clarity Pharmaceuticals Ltd Daily Average True Range (ATR) ChartClarity Pharmaceuticals Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Clarity Pharmaceuticals Ltd. The current obv is 30,055,573.

Clarity Pharmaceuticals Ltd Daily On-Balance Volume (OBV) ChartClarity Pharmaceuticals Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Clarity Pharmaceuticals Ltd. The current mfi is 50.88.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Clarity Pharmaceuticals Ltd Daily Money Flow Index (MFI) ChartClarity Pharmaceuticals Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Clarity Pharmaceuticals Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-12-31STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-01-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-01-09STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-10MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-01-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-01-14STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-01-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-01-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-01-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-03BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-14STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-02-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-06BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-18RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-24STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-31BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-04ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-08MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-09STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-24CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-30STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-01WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-02BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-05-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-15STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-22STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Clarity Pharmaceuticals Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Clarity Pharmaceuticals Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.512
Ma 20Greater thanMa 502.355
Ma 50Greater thanMa 1002.234
Ma 100Greater thanMa 2002.952
OpenGreater thanClose2.270
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Clarity Pharmaceuticals Ltd with someone you think should read this too:
  • Are you bullish or bearish on Clarity Pharmaceuticals Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Clarity Pharmaceuticals Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Clarity Pharmaceuticals Ltd

I send you an email if I find something interesting about Clarity Pharmaceuticals Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Clarity Pharmaceuticals Ltd.

Receive notifications about Clarity Pharmaceuticals Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.